This work was undertaken by the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (APM) as a demonstration project in developing clinical guidelines relevant to palliative care from a pragmatic approach to literature review and grading of clinical evidence. CANCERLIT and Embase were searched for relevant papers written in English, published since 1980. Each study identified was rated against agreed criteria for levels of evidence. Most studies were not specifically designed to define speed of response, and were not undertaken in palliative care patients. Thus, careful reading and grading of each study was necessary. Sufficient evidence was identified to make recommendations for clinical practice in a ...
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer ar...
Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, a...
PURPOSE: When treating metastatic bone disease, relief of bone pain is often a key outcome. Because ...
Background: Bisphosphonates and denosumab are well-established therapies to reduce the frequency and...
Metastatic bone disease is a frequent cause of morbidity in advanced cancer patients with a subseque...
Background: Prostate cancer is the most common cancer in men in many western countries. It is charac...
Bisphosphonates have proven effectiveness in preventing skeletal-related events (SREs) in advanced b...
Metastatic bone disease in patients with advanced cancer is frequently associated with skeletal comp...
Bisphosphonates (BPs) work well in stopping, decreasing the prevalence, and putting off the beginnin...
The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignanc...
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with...
Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of...
Introduction:Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying...
Bone metastases are a common event in advanced cancer. Breast, lung, prostate and thyroid neoplasms ...
Pain from metastases of primitive cancer is the first sympthom of disease in 15-20% of patients and ...
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer ar...
Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, a...
PURPOSE: When treating metastatic bone disease, relief of bone pain is often a key outcome. Because ...
Background: Bisphosphonates and denosumab are well-established therapies to reduce the frequency and...
Metastatic bone disease is a frequent cause of morbidity in advanced cancer patients with a subseque...
Background: Prostate cancer is the most common cancer in men in many western countries. It is charac...
Bisphosphonates have proven effectiveness in preventing skeletal-related events (SREs) in advanced b...
Metastatic bone disease in patients with advanced cancer is frequently associated with skeletal comp...
Bisphosphonates (BPs) work well in stopping, decreasing the prevalence, and putting off the beginnin...
The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignanc...
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with...
Metastatic bone disease puts an enormous burden on patients and health care resources. Disruption of...
Introduction:Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying...
Bone metastases are a common event in advanced cancer. Breast, lung, prostate and thyroid neoplasms ...
Pain from metastases of primitive cancer is the first sympthom of disease in 15-20% of patients and ...
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer ar...
Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, a...
PURPOSE: When treating metastatic bone disease, relief of bone pain is often a key outcome. Because ...